Colinz Laboratories Limited (BOM:531210)

India flag India · Delayed Price · Currency is INR
47.73
-2.27 (-4.54%)
At close: May 6, 2026
Market Cap124.70M -1.9%
Revenue (ttm)58.40M -12.9%
Net Income4.94M +2.4%
EPS1.96 +2.6%
Shares Out2.52M
PE Ratio25.25
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume320
Average Volume790
Open52.00
Previous Close50.00
Day's Range47.65 - 52.50
52-Week Range36.11 - 87.91
Beta-0.10
RSI56.11
Earnings DateApr 29, 2026

About Colinz Laboratories

Colinz Laboratories Limited manufactures, markets, and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, ointments, injectables, creams, syrups, suppositories, etc.; and specialized products for gynecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, pegylated liposome doxorubicin,... [Read more]

Industry Pharmaceutical Preparations
Founded 1986
Employees 65
Stock Exchange Bombay Stock Exchange
Ticker Symbol 531210
Full Company Profile

Financial Performance

In fiscal year 2025, Colinz Laboratories's revenue was 65.28 million, a decrease of -7.14% compared to the previous year's 70.30 million. Earnings were 4.97 million, an increase of 2.03%.

Financial Statements